Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
The company manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally.
Neuland Laboratories Ltd., is a listed public company incorporated on 07 January, 1984. It is classified as a public limited company and is located in , Telangana. It's authorized share capital is INR 44.00 cr and the total paid-up capital is INR 12.83 cr.
Read more
This action will use 1 of your credits. Are you sure you want to go ahead?
** All rupee values in INR crores. Based on March 2023 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
State | Type | Address |
---|
Read more
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Networth | |||||
Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Solvency + | |||||
Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Liquidity + | |||||
Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Performance | |||||
Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Return + | |||||
Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Efficiency + | |||||
Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Working Capital | |||||
Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
SBICap Trustee Company Limited
No. of Loans: 1
Total Amount : 680.1 cr
Axis Bank Limited
No. of Loans: 2
Total Amount : 3.1 cr
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Director | Prasad Raghava Menon | 00005078 | 2 years |
Director | Homi Rustam Khusrokhan | 00005085 | 6 years |
Whole-time Director | Ramamohan Rao Davuluri
Shareholder
|
00107737 | 41 years |
Whole-time Director | Sucheth Rao Davuluri
Shareholder
|
00108880 | 21 years |
Director | Nirmala Srinivasa Murthy | 00734866 | 10 years |
Director | Sugata Sircar | 01119161 | 1 years |
CFO | Abhijit Majumdar | <HIDDEN> | 2 years |
Director | Pallavi Joshi Bakhru | 01526618 | 1 years |
Whole-time Director | Saharsh Rao Davuluri
Shareholder
|
02753145 | 15 years |
Director | Christopher Cimarusti M | 02872948 | 15 years |
CS | Sarada Bhamidipati | <HIDDEN> | 13 years |
Name | Status | Paid up Capital | Common Directors | Address |
---|---|---|---|---|
CHEMPLAST SANMAR LIMITED |
Active
|
79.1 Cr | 1 | Tamil Nadu |
DATA PATTERNS (INDIA) LIMITED |
Active
|
11.2 Cr | 1 | Tamil Nadu |
THE ANGLO SCOTTISH EDUCATION SOCIETY |
Active
|
0.0 | 1 | Maharashtra |
STRIDES PHARMA SCIENCE LIMITED |
Active
|
92.0 Cr | 1 | Maharashtra |
NEULAND PHARMA RESEARCH PRIVATE LIMITED |
Amalgamated
|
5.0 Cr | 3 | Telangana |
NEULAND HEALTH SCIENCES PRIVATE LIMITED |
Amalgamated
|
12.4 Cr | 3 | Telangana |
ASVI THERAPEUTICS PRIVATE LIMITED |
Active
|
1.0 L | 3 | Telangana |
PATTANCHERU ENVIRO-TECH LIMITED |
Active
|
2.6 Cr | 1 | Telangana |
YPO SOUTH ASIA CHAPTER |
Active
|
0.0 | 1 | Maharashtra |
CATO RESEARCH NEULAND INDIA PRIVATE LIMITED |
Strike Off
|
51.1 L | 2 | Telangana |
PUBLIC AFFAIRS FOUNDATION |
Active
|
0.0 | 1 | Karnataka |
MCKINNON AND CLARKE (INDIA) PRIVATE LIMITED |
Under Liquidation
|
4.2 L | 1 | Maharashtra |
SENSUS METERING SYSTEMS INDIA LIMITED |
Dissolved
|
8.0 Cr | 1 | Maharashtra |
SUGATA SIRCAR ADVISORY PRIVATE LIMITED |
Active
|
1.0 L | 1 | Haryana |
AZURE POWER INDIA PRIVATE LIMITED |
Active
|
6.9 Cr | 1 | Delhi |
GRANT THORNTON ADVISORY PRIVATE LIMITED |
Active
|
11.6 L | 1 | Delhi |
HINDUSTAN ZINC LIMITED |
Active
|
845.1 Cr | 1 | Rajasthan |
FACOR POWER LIMITED |
Amalgamated
|
241.1 Cr | 1 | Odisha |
VEDANTA LIMITED |
Active
|
391.1 Cr | 1 | Maharashtra |
GRANT THORNTON BHARAT LLP |
Active
|
32.8 Cr | 1 | Delhi |
GABRIEL INDIA LIMITED |
Active
|
14.4 Cr | 1 | Maharashtra |
Name | State / Country | Incorporation Year | Paidup Capital |
---|---|---|---|
Ne u l a n d Laboraotires Inc | United States | - | - |
Neuland Laboratories K.K. | Japan | - | - |
The incorporation date of NEULAND LABORATORIES LTD. is 07 January, 1984
The authorized share capital of NEULAND LABORATORIES LTD. is INR ₹ 44.0 Cr.
The paid-up capital of NEULAND LABORATORIES LTD. is INR ₹ 12.8 Cr.
The registered address of NEULAND LABORATORIES LTD. is 11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad Hyderabad Telangana - 500033
The CIN number of NEULAND LABORATORIES LTD. is L85195TG1984PLC004393.